Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EGTX.ST
- Price
- 4.55
- Stock movement up
- +0.07 (1.68%)
- Company name
- Egetis Therapeutics AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.81B
- Ent value
- 1.98B
- Price/Sales
- 32.69
- Price/Book
- 6.53
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 8.73
- PEG
- -
- EPS growth
- -0.89%
- 1 year return
- -22.88%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-16
DIVIDENDS
EGTX.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 32.69 |
| Price to Book | 6.53 |
| EV to Sales | 35.80 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 398.06M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 0.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 145.70M |
| Net receivables | 43.00M |
| Total current assets | 198.30M |
| Goodwill | 0.00 |
| Intangible assets | 383.70M |
| Property, plant and equipment | 10.40M |
| Total assets | 595.10M |
| Accounts payable | 37.90M |
| Short/Current long term debt | 92.00M |
| Total current liabilities | 247.40M |
| Total liabilities | 317.70M |
| Shareholder's equity | 277.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.45 |
| Daily high | 4.72 |
| Daily low | 4.41 |
| Daily Volume | 878K |
| All-time high | 57.90 |
| 1y analyst estimate | 9.78 |
| Beta | 1.26 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| EGTX.ST | S&P500 | |
| Current price drop from All-time high | -92.14% | -0.50% |
| Highest price drop | -94.78% | -19.00% |
| Date of highest drop | 23 May 2025 | 8 Apr 2025 |
| Avg drop from high | -91.29% | -2.50% |
| Avg time to new high | - | 6 days |
| Max time to new high | 315 days | 89 days |
COMPANY DETAILS
Marketcap
1.81B
Marketcap category
Small-cap
Description
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Employees
40
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Egetis Therapeutics AB (STU:P0F) reports increased revenue and a strengthened cash position, while navigating regulatory hurdles and strategic investments for future growth.
November 28, 2025
As European markets navigate concerns over inflated AI stock valuations and the impact of U.S. interest rate expectations, investors are increasingly focusing on companies with strong fundamentals and...
November 25, 2025
In recent weeks, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.77% amid relief over the reopening of the U.S. federal government, though tempered by ...
November 21, 2025
Amidst a backdrop of mixed global market performances, the European markets recently saw a boost as major stock indexes rose, driven by relief over the reopening of the U.S. federal government. Howeve...
November 20, 2025
As European markets navigate the relief of the U.S. federal government reopening, tempered by cooling sentiment around artificial intelligence, investors are keenly observing growth stocks with high i...
November 20, 2025
As European markets experience a mixed sentiment driven by relief from the U.S. government reopening and tempered enthusiasm around artificial intelligence, investors are increasingly focusing on comp...
November 19, 2025
In recent weeks, the European stock market has experienced a pullback, with major indexes such as Germany's DAX and France's CAC 40 seeing declines amid concerns about overvaluation in artificial inte...
November 14, 2025
As European markets face a pullback amid concerns about overvaluation in artificial intelligence-related stocks, investors are increasingly cautious, with major indexes such as Germany's DAX and Franc...
November 14, 2025
As European markets experience a pullback, with the pan-European STOXX Europe 600 Index ending 1.24% lower amid concerns about overvaluation in AI-related stocks, investors are increasingly focused on...
November 13, 2025
As European markets navigate mixed signals with the pan-European STOXX Europe 600 Index recently pulling back, investor focus remains on growth companies that can thrive despite shifting economic cond...
November 6, 2025
Next page